February 6, 2023

To whom it may concern,

Company Name: Uzabase, Inc. Names of representatives: Yusuke Inagaki, Representative Director and Co-CEO/CTO Taira Sakuma, Representative Director and Co-CEO (Code: 3966, TSE Growth) Contact: Daisuke Chiba, Chief Financial Officer Tel (IR Direct): +81-3-4533-1999

Notice of Delisting of Uzabase's Shares

Uzabase, Inc. (hereinafter referred to as "the Company"), at a meeting of its Board of Directors held on January 6, 2023, resolved to approve the demand for share, etc. cash-out by THE SHAPER, the special controlling shareholder of the Company, pertaining to the Company's common shares and Stock Acquisition Rights (Note 1). The Company hereby announces that as a result, its common shares meet the delisting criteria of the Tokyo Stock Exchange, Inc. and will be delisted as of February 7, 2023.

For details, please refer to the "Announcement of Decision Regarding Demand for Share, etc. Cash-Out by THE SHAPER Co., Approval of the Demand, and Delisting of the Company's Shares" released by the Company on January 6, 2023.

We would like to sincerely thank our shareholders and other stakeholders for continued support of the Company since our listing in 2016.

We look forward to your ongoing understanding and support as we strive to further enhance our corporate value in the future.

- Note 1: The following stock acquisition rights ① to ⑫ are collectively referred to as the "Stock Acquisition Rights."
 - The fourth series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on May 3, 2013 (the "Fourth Series Stock Acquisition Rights") (Exercise period: from May 5, 2013 to May 3, 2023)
 - ② The fifth series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on April 28, 2014 (the "Fifth Series Stock Acquisition Rights") (Exercise period: from May 1, 2014 to March 28, 2024)
 - ③ The eighth series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on June 19, 2015 (the "Eight Series Stock Acquisition Rights") (Exercise period: from July 2, 2015 to March 27, 2025)
 - The ninth series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on January 4, 2016 (the "Ninth Series Stock Acquisition Rights") (Exercise period: from January 6, 2016 to December 18, 2025)
 - (5) The 11th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on July 15, 2016 (the "11th Series Stock Acquisition Rights") (Exercise period: from July 20, 2016 to December 18, 2025)
 - (6) The 12th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on July 15, 2016 (the "12th Series Stock Acquisition Rights") (Exercise period: from July 20, 2016 to December 18, 2025)
 - The 13th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on May 22, 2017 (the "13th Series Stock Acquisition Rights") (Exercise period: from April 1, 2023 to June 18, 2027)
 - (8) The 14th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on May 22, 2017 (the "14th Series Stock Acquisition Rights") (Exercise period: from April 1, 2022 to June 18, 2027)
 - (9) The 15th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on May 22, 2017 (the "15th Series Stock Acquisition Rights")

(Exercise period: from April 1, 2021 to June 18, 2027)

- The 16th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on March 16, 2018 (the "16th Series Stock Acquisition Rights") (Exercise period: from February 15, 2019 to July 31, 2024)
- The 17th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on March 16, 2018 (the "17th Series Stock Acquisition Rights") (Exercise period: from February 15, 2019 to July 31, 2024)
- 12 The 28th series stock acquisition rights issued based on the resolution at the meeting of the Company's Board of Directors held on April 14, 2022 (the "28th Series Stock Acquisition Rights") (Exercise period: from April 30, 2022 to April 29, 2027)

End of Notice